Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing product pipeline of pharma companies
4.1.1.2. Rising advancements in technologies leading to the development of new drugs
4.1.2. Restraints:
4.1.2.1. High cost associated with treatment
4.1.2.2. High risk of side effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Uveitis Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
7.1.2. Market Attractiveness Index, By Uveitis Type
7.2. Anterior Uveitis *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Intermediate Uveitis
7.4. Posterior Uveitis
7.5. Pan Uveitis
8. By Medications
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.2.3. Bethamethasone
8.2.4. Dexamethasone
8.2.5. Cortisone
8.2.6. Triamcinolone
8.2.7. Methylprednisolone
8.3. Anti-Rheumatic Drugs
8.3.1. Mycophenolate
8.3.2. Cyclosporine
8.3.3. Azathioprine
8.3.4. Tacrolimus
8.4. Cycloplegic-Mydriatic Drugs
8.4.1. Tropicamide
8.4.2. Cyclopentolate
8.4.3. Phenylephrine
8.4.4. Homatropine
8.4.5. Atropine
8.5. Immunomodulatory Therapy
8.5.1. Azathioprine
8.5.2. Methotrexate
8.5.3. Mycophenolate Mofetil
8.5.4. Cyclosporine
8.6. Biological Therapy
8.6.1. Infliximab
8.6.2. Adalimumab
8.6.3. Daclizumab
8.6.4. Interferon-Alfa
8.7. Anti-Viral Drugs
8.7.1. Aciclovir
8.7.2. Valaciclovir
8.8. Others
9. By Medication Form
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
9.1.2. Market Attractiveness Index, By Medication Form
9.2. Eye Drops *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Pills
9.4. Injections
9.5. Implants
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Novartis AG *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. AbbVie
13.3. Johnson & Johnson Services, Inc.
13.4. Amgen
13.5. Alimera Sciences
13.6. Bausch & Lomb Incorporated.
13.7. Kiora Pharmaceuticals, Inc.
13.8. Santen Pharmaceutical Co., Ltd.
13.9. EyePoint Pharmaceuticals, Inc.
13.10. Clearside Biomedical
LIST NOT EXHAUSTIVE
14. Global Uveitis Market – DataM
14.1. Appendix
14.2. About Us and Medications
14.3. Contact Us